Investor Relations

Corporate profile

Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.

Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions.

DOWNLOAD PDFLatest corporate presentation

Investment Highlights

Strong IP strategy for novel therapeutic modality.

Favorable safety profile demonstrated across several clinical studies.

Proposed MOA supported by clinical data.

Optimized manufacturing process yielding ready-to-use doses of off-the-shelf cell therapy platform.

Multi-billion-dollar market opportunity in several inflammatory disease markets with high unmet need.

Seasoned management team with a track record of successfully advancing therapies through regulatory approval.

Recent news releases

View all
26

September

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency authorized the initiation of the Phase II stage of the Company's multi-c...
24

September

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at the c...
23

July

First study of AllocetraTM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis1, and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutic...